Ectodysplasin A2 Receptor Antikörper

Produktnummer ABIN501133

Dieser Kaninchen Polyklonal Antikörper erkennt spezifisch Ectodysplasin A2 Receptor in WB, IHC (p) und EIA. Er zeigt eine Reaktivität gegenüber Human.

Kurzübersicht für Ectodysplasin A2 Receptor Antikörper (ABIN501133)

Target: Ectodysplasin A2 Receptor (EDA2R)

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser Ectodysplasin A2 Receptor Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Enzyme Immunoassay (EIA)

Produktdetails anti-Ectodysplasin A2 Receptor Antikörper

Spezifität: This antibody detects EDA2R / TNFRSF27.

Kreuzreaktivität (Details): Species reactivity (tested):Human

Aufreinigung: Affiinity chromatography

Immunogen: XEDAR antibody was raised against recombinant human XEDAR.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: ELISA. Western blot: 0.5 - 1 μg/mL. Immunohistochemistrry on paraffin sections.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: PBS containing 0.02 % sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freezing and thawing.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store at 2 - 8 °C for up to one month or (in aliquots) at -20 °C for longer.

Details zu Ectodysplasin A2 Receptor

Target: Ectodysplasin A2 Receptor (EDA2R)

Andere Bezeichnung: EDA2R / TNFRSF27

Hintergrund: X-linked ectodysplasin-A2 receptor (XEDAR) is a recently isolated member of the tumor necrosis factor receptor family that is highly expressed during embryonic development and binds to ectodysplatin-A2 (EDA-A2) (1). Two predominantly expressed isoforms, XEDAR-s and XEDAR-L, differ by only a 21-amino region at the juxtamembrane region of the cytoplasmic domain. Neither isoform possesses a death domain and both have been shown to act mainly through TRAF3 and TRAF6 to activate the NF-kappaB and JNK pathways (2). Cells transfected with XEDAR and treated with EDA-A2 cause the assembly of a secondary complex containing FADD, caspase-8 and caspase-10, leading to the activation caspase-8 and caspase-3, and finally apoptosis (3). The EDA-A2-induced apoptosis is dependent on caspase-9 activation, as various pharmacological and genetic inhibitors of caspase-8 blocked apoptosis following EDA-A2 treatment (3).Synonyms: EDA-A2 receptor, Tumor necrosis factor receptor superfamily member 27, UNQ2448/PRO5727/PRO34080, X-linked ectodysplasin-A2 receptor, XEDAR

Gen-ID: 60401